AOA Dx Enrolls First Patient in APEX Study, Advancing Proprietary Biobank and Clinical Infrastructure
Denver, CO | May 5, 2026 — AOA Dx, Inc. (“AOA”), a diagnostics company focused on transforming the early identification of ovarian cancer, today announced the enrollment of the first participant in its APEX study, a prospective, multi-site study being conducted across the United States and Europe, designed to expand the company’s industry-leading biobank of women […]